News | September 10, 2024
Briefs: Wanbury and Bafna Pharmaceuticals
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
The recent inspection covered both cGMP and PAI processes
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Konieczny has served as Interim CEO since April 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Subscribe To Our Newsletter & Stay Updated
